Editorial: Bioavailability, bioequivalence, generics and switching or substitution: Science, emotion and vested interests

Journal of Pharmacy Practice and Research

Volumn 40, Issue 2, 2010, Pages 90-91

  Ramzan, Iqbal ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; GENERIC DRUG;

BIOEQUIVALENCE; DRUG BIOAVAILABILITY; DRUG COST; DRUG FORMULATION; DRUG INDUSTRY; EDITORIAL; HEALTH CARE COST; HUMAN; PRESCRIPTION;

EID: 77954871140     PISSN: 1445937X     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.2055-2335.2010.tb00511.x     Document Type: Editorial

References (4)

1. Pearce GA, McLachlan AJ, Ramzan I. Bioequivalence: how, why, and what does it really mean? J Pharm Pract Res 2004;34:195-200.
2. McKinnon RA, Yu C Y. Biosimilars are not (bio) generics [editorial]. Aust Prescr 2009;32:146-7.
3. Power DA, Ford D. Biological drugs and the coming of biosimilars. J Pharm Pract Res 2008;38:137-9.
4. Ramzan I, McLachlan AJ. Anti-epileptics switching problem? ⋯ but where is the evidence? Aust J Pharm 2005;86:772, 820.